Federated Hermes Inc. Boosts Stock Position in Nkarta, Inc. (NASDAQ:NKTX)

Federated Hermes Inc. raised its position in shares of Nkarta, Inc. (NASDAQ:NKTX) by 28,478.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 135,749 shares of the company’s stock after purchasing an additional 135,274 shares during the quarter. Federated Hermes Inc. owned 0.27% of Nkarta worth $802,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in NKTX. Meeder Asset Management Inc. purchased a new stake in shares of Nkarta in the second quarter worth about $26,000. American Century Companies Inc. boosted its stake in shares of Nkarta by 49.9% in the second quarter. American Century Companies Inc. now owns 72,205 shares of the company’s stock worth $427,000 after buying an additional 24,033 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Nkarta by 11,164.3% in the second quarter. Acadian Asset Management LLC now owns 303,461 shares of the company’s stock worth $1,792,000 after buying an additional 300,767 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Nkarta by 65.1% in the second quarter. Rhumbline Advisers now owns 84,011 shares of the company’s stock worth $496,000 after buying an additional 33,117 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Nkarta by 80.2% in the second quarter. Bank of New York Mellon Corp now owns 172,162 shares of the company’s stock worth $1,017,000 after buying an additional 76,612 shares during the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Insider Buying and Selling at Nkarta

In other Nkarta news, insider Alicia J. Hager sold 3,396 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $8.00, for a total transaction of $27,168.00. Following the completion of the transaction, the insider now owns 103,819 shares of the company’s stock, valued at $830,552. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 8.70% of the company’s stock.

Nkarta Trading Down 3.2 %

NASDAQ NKTX opened at $5.21 on Monday. The stock has a market capitalization of $257.46 million, a price-to-earnings ratio of -2.22 and a beta of 0.81. Nkarta, Inc. has a twelve month low of $1.28 and a twelve month high of $16.24. The stock has a 50-day moving average of $5.80 and a 200 day moving average of $7.10.

Nkarta (NASDAQ:NKTX) last announced its earnings results on Tuesday, August 13th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.15. Equities analysts predict that Nkarta, Inc. will post -1.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NKTX. Raymond James upgraded Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 target price on the stock in a research note on Wednesday, August 14th. HC Wainwright reduced their price target on Nkarta from $23.00 to $22.00 and set a “buy” rating for the company in a report on Thursday, August 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $13.00 price target on shares of Nkarta in a report on Wednesday, August 14th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $18.20.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.